Fay AP, et al. - The overall survival (OS) was investigated for patients with metastatic renal cell carcinoma (mRCC) treated in the era of targeted therapy by geographic region. Clinical trials across different geographic regions showed similar OS among patients enrolled, despite different baseline characteristics. Potential differences in outcomes might be due to access to clinical trials as well as disease biology, adverse event (AE) reporting, and quality of care.

Methods

• Patients with mRCC who were treated during phase 2 or 3 clinical trials were included in this pooled analysis.
• Collection of clinical characteristics and survival data was performed, and with the Kaplan-Meier method and log-rank test, statistical analyses were performed in univariable analysis.

Results

• The analysis included 4,736 patients, and according to geographic region, patient characteristics differed.
• Observations revealed no statistically significant differences in OS when the United States/Canada (USC) was compared with Latin America, Asia/Oceania/Africa, or Eastern Europe.
• Univariable analysis demonstrated differences in OS among patients enrolled in trials in USC compared with Western Europe (20.3 vs 17.4 months; hazard ratio, 1.15; 95% CI, 1.03 to 1.3; P=.015); however, it did not differ in a multivariable analysis.
• USC more frequently displayed all-grade treatment-related adverse events (AEs). The groups displayed no significant differences in grade 3 to 5 AEs.